Testing the Effect of Raltegravir on Persistent de Novo HIV Infection in Virologic Responders to Antiretroviral Therapy ( RALNOVO )

Trial Profile

Testing the Effect of Raltegravir on Persistent de Novo HIV Infection in Virologic Responders to Antiretroviral Therapy ( RALNOVO )

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2017

At a glance

  • Drugs Raltegravir (Primary)
  • Indications HIV-1 infections
  • Focus Biomarker; Pharmacodynamics
  • Acronyms RALNOVO
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 04 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
    • 25 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top